iQone Healthcare Group

Executive Summary

iQone Healthcare Group is a Swiss-based commercial-stage biosimilars company and a wholly-owned subsidiary of Celltrion Inc., established in 2015. It operates as the exclusive commercial partner for Celltrion's biosimilar portfolio in Switzerland, focusing on providing high-quality, cost-effective alternatives to reference biologics in therapeutic areas such as rheumatology, gastroenterology, and oncology. The company leverages Celltrion's global manufacturing and development expertise while tailoring its approach to the unique Swiss healthcare system, ensuring rapid patient access and healthcare professional support. With a patient-centric mission to reduce healthcare costs and improve treatment availability, iQone has built a robust commercial infrastructure and market access capabilities. Its portfolio includes several biosimilars for key indications, and it continues to expand through the introduction of new products from Celltrion's pipeline. By acting as a dedicated local entity, iQone provides streamlined supply chains and customized services, positioning itself as a key player in the Swiss biosimilar market. The company's strong parent backing and specialized focus underpin its growth prospects in an increasingly competitive landscape.

Upcoming Catalysts (preview)

• Q4 2026Swissmedic approval for a new biosimilar from Celltrion's pipeline (e.g., CT-P47 for inflammatory bowel disease)70% success